HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions

Lowy, Douglas R.

doi:10.1172/jci85446

Cited by 74 publications

(58 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…74 HPV L1 major capsid protein, which self-assembles into VLPs when expressed heterologously, is the main component of the currently available vaccines against cervical cancer. 75 However, the commercial HPV vaccines are expensive and still inaccessible to the majority of the population especially in economically disadvantaged regions. Therefore, this is a great need for the development of an alternative system for the production of HPV vaccines that can be provided by public health programs.…”

Section: Recombinant Protein Subunit Vaccinesmentioning

confidence: 99%

Recent advances in the production of recombinant subunit vaccines inPichia pastoris

2016

View full text Add to dashboard Cite

Recombinant protein subunit vaccines are formulated using defined protein antigens that can be produced in heterologous expression systems. The methylotrophic yeast Pichia pastoris has become an important host system for the production of recombinant subunit vaccines. Although many basic elements of P. pastoris expression system are now well developed, there is still room for further optimization of protein production. Codon bias, gene dosage, endoplasmic reticulum protein folding and culture condition are important considerations for improved production of recombinant vaccine antigens. Here we comment on current advances in the application of P. pastoris for the synthesis of recombinant subunit vaccines.

show abstract

Section: Recombinant Protein Subunit Vaccinesmentioning

confidence: 99%

Recent advances in the production of recombinant subunit vaccines inPichia pastoris

2016

View full text Add to dashboard Cite

show abstract

“…Current recommendations for young adolescent immunization programs may provide coverage of about 90% of HPV infections based on the prevalence of HR-HPV types on cervical cancer globally [92]. More recently, in Europe, the World Health Organization (WHO) has proposed a two-dose schedule since 2014, based on data that indicated that a two-dose schedule would provide the same immunogenicity and safety compared to the previous three-dose schedule, when administered to young adolescents (i.e., below 15 years of age) [93,94]. …”

Section: Screening a Vaccinated Population - What Has And Will Chmentioning

confidence: 99%

Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention

Gradíssimo

Burk

2017

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

INTRODUCTION Human papillomavirus (HPV)-related cancers can be averted by type-specific vaccination (primary prevention) and/or through detection and ablation of precancerous cervical lesions (secondary prevention). This review presents current challenges to cervical cancer screening programs, focusing on recent molecular advances in HPV testing and potential improvements on risk stratification. AREAS COVERED High-risk (HR)-HPV DNA detection has been progressively incorporated into cervix cancer prevention programs based on its increased sensitivity. Advances in next-generation sequencing (NGS) are being rapidly applied to HPV typing. However, current HPV DNA tests lack specificity for identification of cervical precancer (CIN3). HPV typing methods were reviewed based on published literature, with a focus on these applications for screening and risk stratification in the emerging complex clinical scenario post-vaccine introduction. In addition, the potential for NGS technologies to increase specificity is discussed in regards to reflex testing of specimens for emerging biomarkers for cervix precancer/cancer. EXPERT COMMENTARY Integrative multi-disciplinary molecular tests accurately triaging exfoliated cervical specimens will improve cervical cancer prevention programs while simplifying healthcare procedures in HPV-infected women. Hence, the concept of a “liquid-biopsy” (i.e., “molecular” Pap test) highly specific for early identification of cervical precancerous lesions is of critical importance in the years to come.

show abstract

“…Studies conducted after each vaccine was approved by the FDA indicated that when young adolescents were given 2 vaccine doses separated by at least 6 months, the resulting HPV antibody titers were at least as high as those in the women receiving 3 doses in the respective efficacy trials, which led to regulatory approval for 2 doses in young adolescents. 7 …”

Section: Reducing Vaccine Doses and Increasing Uptakementioning

confidence: 99%

Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection

Lowy

Schiller

2017

JAMA

Self Cite

View full text Add to dashboard Cite

show abstract

HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions

Cited by 74 publications

References 51 publications

Recent advances in the production of recombinant subunit vaccines inPichia pastoris

Recent advances in the production of recombinant subunit vaccines inPichia pastoris

Molecular tests potentially improving HPV screening and genotyping for cervical cancer prevention

Preventing Cancer and Other Diseases Caused by Human Papillomavirus Infection

Contact Info

Product

Resources

About